Relay Therapeutics Inc. (RLAY) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, USA. The company is focused on discovering and developing small molecule therapies for various diseases by leveraging its expertise in protein motion.
Relay's lead product candidate is RLY-1971, an investigational small molecule therapy designed to inhibit the activity of SHP2, a protein that plays a key role in the growth and survival of cancer cells. RLY-1971 is currently being evaluated in multiple Phase 1 clinical trials for the treatment of various solid tumors and hematologic malignancies. Relay is also developing other product candidates for the treatment of various diseases, including RLY-PI3K1047, a small molecule inhibitor of PI3K-alpha, a protein that is frequently mutated in various cancers.
In October 2021, Relay announced positive interim data from its Phase 1 clinical trial of RLY-1971 in patients with advanced solid tumors. The data showed that RLY-1971 was generally well-tolerated and demonstrated encouraging signs of clinical activity, including partial responses and stable disease in multiple tumor types. The company plans to continue the development of RLY-1971 and expects to initiate additional clinical trials in the coming months.
As of September 30, 2021, Relay had cash, cash equivalents, and marketable securities of $724.3 million. The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.
Relay's stock is listed on the NASDAQ stock exchange and has a market capitalization of approximately $4.4 billion as of February 21, 2023.
|
